renal
International IgA Nephropathy Prediction Tool
Predicts 50% eGFR decline or end-stage renal disease in IgA nephropathy at 5 and 20 years. Combines clinical and histological (Oxford MEST-C) criteria.
References
- Barbour SJ et al. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int. 2016;89(1):167–175.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.